Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 2/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3856688 | 0.88 | DRD3 (0.44) | HRH3APPMAPK1LMNACYP1A2 | |
| SCHEMBL5157848 | 0.88 | APP (0.44) | HRH3APPCYP2C19MAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL5456304 | 0.86 | APP (0.43) | HRH3APPCYP2C19MAPTMAPK1 | |
| SCHEMBL23928190 | 0.81 | HRH3 (0.45) | HRH3NOS2NOS1CYP2C19CYP1A2 | |
| SCHEMBL10798745 | 0.81 | TAAR1 (0.52) | NOS2CYP2C19MAPTSCN9A | |
| SCHEMBL81430 | 0.81 | MAPT (0.67) | HRH3NOS2NOS1CYP2C19MAPT | |
| SCHEMBL3989340 | 0.81 | PHLPP2 (0.43) | HRH3APPMAPTPHLPP2MAPK1 | |
| SCHEMBL14663491 | 0.80 | APP (0.42) | HRH3APPMAPTMAPK1LMNA | |
| SCHEMBL250769 | 0.80 | KEAP1 (0.49) | HRH3NCF1NOS2NOS1CYP2C19 | |
| SCHEMBL14596281 | 0.80 | TSHR (0.50) | HRH3APPCYP2C19MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111566100-B | Pyrimidine compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-20210101881-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF AND MEDICAL USE THEREOF | ANCUREALL PHARMACEUTICAL (SHANGHAI) CO., LTD. (CN) | 2021-04-08 | — | — | US | disclosed |
| WO-2019154177-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF AND MEDICAL USE THEREOF | 恩瑞生物医药科技（上海）有限公司 | 2019-08-15 | — | — | WO | disclosed |
| WO-2014183300-A1 | VEGFR TYROSINE KINASE INHIBITORS | SUZHOU VIVOTIDE BIOTECHNOLOGIES CO., LTD. (CN) | 2014-11-20 | — | — | WO | disclosed |
| US-6855710-B2 | Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-15 | — | — | US | disclosed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | disclosed |
| US-20040058978-A1 | Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-03-25 | — | — | US | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |
| EP-1115704-B1 | NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-06-18 | — | — | EP | disclosed |
| CN-1319090-A | Novel substuted indolimones, their preparation process and use as medicine | BOEHRINGER INGELHEIM PHARMA (DE) | 2001-10-24 | — | — | CN | disclosed |
| EP-1115704-A1 | NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES | Boehringer Ingelheim Pharma KG (DE) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000018734-A1 | NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-04-06 | — | — | WO | disclosed |
| EP-0142777-B1 | BASIC TRIPHENDIOXAZINE DYES, THEIR PREPARATION AND THEIR USE | BAYER AG (DE) | 1987-12-23 | — | — | EP | disclosed |
| EP-0148390-A2 | Basic triphendioxazine dyes, their manufacture and their use | BAYER AG (DE) | 1985-07-17 | — | — | EP | disclosed |
| EP-0142777-A2 | Basic triphendioxazine dyes, their preparation and their use | BAYER AG (DE) | 1985-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210101881-A1 | PYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF AND MEDICAL USE THEREOF | CDK9, CDK19, CDK6 | HRH3 2357/4885APP 3757/4885NCF1 2666/4885 |
| US-20040058978-A1 | Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs | CDK1, CDK2, CDK3 | HRH3 1204/4885APP 4718/4885NCF1 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.